PriceTargets.com logo

Cardiovascular Systems - CSII Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$20.00 As of 05/11/2023 01:00 AM ET
+0 (0.00%)
Get New Cardiovascular Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSII

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiovascular Systems in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $20.00.

This chart shows the closing price for CSII for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Cardiovascular Systems. This rating has held steady since January 2024, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/9/2023Lake Street CapitalDowngradeBuy ➝ Sell
12/21/2022BarclaysInitiated CoverageEqual Weight$15.00
12/14/2022Lake Street CapitalInitiated CoverageBuy$25.00
3/2/2022Bank of AmericaInitiated CoverageUnderperform ➝ Underperform
2/4/2022Leerink PartnersLower TargetOutperform$25.00 ➝ $20.00
11/17/2021Needham & Company LLCDowngradeBuy ➝ Hold
11/10/2021OppenheimerLower TargetOutperform$48.00 ➝ $40.00
11/10/2021GuggenheimDowngradeBuy ➝ Neutral
11/10/2021Leerink PartnersLower TargetOutperform$45.00 ➝ $40.00
9/26/2021Leerink PartnersReiterated RatingBuy
9/23/2021Needham & Company LLCLower TargetBuy$50.00 ➝ $49.00
7/23/2021Leerink PartnersSet TargetBuy$38.75
7/16/2021Northland SecuritiesReiterated RatingBuy$45.00
5/24/2021BarclaysInitiated CoverageEqual Weight$43.00
3/17/2021OppenheimerReiterated RatingBuy$48.00
2/15/2021AegisReiterated RatingBuy
2/4/2021Needham & Company LLCBoost TargetBuy$47.00 ➝ $50.00
12/16/2020Northland SecuritiesBoost TargetOutperform$40.00 ➝ $45.00
12/14/2020Leerink PartnersBoost TargetOutperform$45.00 ➝ $50.00
11/5/2020Needham & Company LLCBoost TargetBuy$44.00 ➝ $47.00
10/16/2020Needham & Company LLCReiterated RatingBuy$44.00
8/12/2020AegisBoost TargetBuy$45.00 ➝ $47.00
8/5/2020Leerink PartnersBoost TargetOutperform$40.00 ➝ $45.00
7/22/2020Northland SecuritiesInitiated CoverageOutperform$40.00
7/17/2020BarclaysInitiated CoverageOverweight$45.00
6/19/2020AegisInitiated CoverageBuy$45.00
6/11/2020Needham & Company LLCUpgradeHold ➝ Buy$44.00
5/6/2020Needham & Company LLCReiterated RatingHold
5/6/2020Lake Street CapitalLower TargetBuy$54.00 ➝ $48.00
4/28/2020Leerink PartnersLower TargetOutperform$60.00 ➝ $50.00
4/19/2020OppenheimerInitiated CoverageOutperform$47.00
4/6/2020OppenheimerInitiated CoverageOutperform$47.00
4/3/2020Lake Street CapitalLower TargetBuy$60.00 ➝ $54.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cardiovascular Systems logo
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.
Read More

Today's Range

Now: $20.00
Low: $20.00
High: $20.00

50 Day Range

MA: $19.98
Low: $19.87
High: $20.00

52 Week Range

Now: $20.00
Low: $12.26
High: $20.57

Volume

4,300 shs

Average Volume

765,906 shs

Market Capitalization

$843.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiovascular Systems?

The following equities research analysts have issued reports on Cardiovascular Systems in the last year: StockNews.com.
View the latest analyst ratings for CSII.

What is the current price target for Cardiovascular Systems?

0 Wall Street analysts have set twelve-month price targets for Cardiovascular Systems in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cardiovascular Systems in the next year.
View the latest price targets for CSII.

What is the current consensus analyst rating for Cardiovascular Systems?

Cardiovascular Systems currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CSII.

What other companies compete with Cardiovascular Systems?

Other companies that are similar to Cardiovascular Systems include Integra LifeSciences, AtriCure, Alphatec, Orthofix Medical and Surmodics. Learn More about companies similar to Cardiovascular Systems.

How do I contact Cardiovascular Systems' investor relations team?

Cardiovascular Systems' physical mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company's listed phone number is (651) 259-1600 and its investor relations email address is [email protected]. The official website for Cardiovascular Systems is www.csi360.com. Learn More about contacing Cardiovascular Systems investor relations.